Publications by authors named "Jacques Vargaftig"

Claim this Profile
P
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
Sara K Silbert, Alexander W Rankin, Chloe N Hoang, Alexandra Semchenkova, Regina M Myers, Jacques Vargaftig

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.
Amira Marouf, Sammara Chaubard, Raphaël Liévin, Jean-Marie Michot, Nicolas Molinari, Jacques Vargaftig

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.
Adrien Joseph, Stéphanie Harel, Laurent Mesnard, Cédric Rafat, Silène Knapp, Jacques Vargaftig

Nephrol Dial Transplant· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Sammara Chaubard, Amira Marouf, David Lavergne, François Lemonnier, Julien Rossignol, Jacques Vargaftig

Br J Haematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Jacques Vargaftig

Clin Cancer Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Auriane Lesieur, Xavier Thomas, Olivier Nibourel, Nicolas Boissel, Laurène Fenwarth, Jacques Vargaftig

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, Florian Renosi, Eve Poret, Jacques Vargaftig

Blood Adv· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Nicolas Delanoy, Jean-Marie Michot, Thibault Comont, Nora Kramkimel, Julien Lazarovici, Jacques Vargaftig

Lancet Haematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia xenograft success prediction: Saving time.
Emmanuel Griessinger, Jacques Vargaftig, Stuart Horswell, David C Taussig, John Gribben

Exp Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related bone marrow failure following anti-PD1 therapy.
Jean-Marie Michot, Jacques Vargaftig, Charlotte Leduc, Gilles Quere, Barbara Burroni

Eur J Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Caroline Houillier, Hervé Ghesquières, Cécile Chabrot, Carole Soussain, Guido Ahle, Jacques Vargaftig

J Neurooncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Laetitia Souchet, Vincent Levy, Maya Ouzegdouh, Jérôme Tamburini, Alain Delmer, Jacques Vargaftig

Am J Hematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Ludovic Nguyen-Them, Myrto Costopoulos, Marie-Laure Tanguy, Caroline Houillier, Sylvain Choquet, Jacques Vargaftig

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.
Emmanuel Griessinger, Fernando Anjos-Afonso, Jacques Vargaftig, David C Taussig, François Lassailly

Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.
Emmanuel Griessinger, Fernando Anjos-Afonso, Irene Pizzitola, Kevin Rouault-Pierre, Jacques Vargaftig

Stem Cells Transl Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Carole Soussain, Sylvain Choquet, Emmanuelle Fourme, Daniel Delgadillo, Krimo Bouabdallah, Jacques Vargaftig

Haematologica· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-related changes in human hematopoietic stem/progenitor cells.
Klaudia Kuranda, Jacques Vargaftig, Philippe de la Rochere, Christine Dosquet, Dominique Charron

Aging Cell· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.
Arnaud Gandillet, Sophie Park, François Lassailly, Emmanuel Griessinger, Jacques Vargaftig

Leukemia· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
David C Taussig, Jacques Vargaftig, Farideh Miraki-Moud, Emmanuel Griessinger, Kirsty Sharrock

Blood· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
Marion Gabillot-Carré, Yves Lepelletier, Martine Humbert, Paulo de Sepuvelda, Nadine Ben Hamouda, Jacques Vargaftig

Blood· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Léa Tourneur, Stéphanie Delluc, Vincent Lévy, Françoise Valensi, Isabelle Radford-Weiss, Jacques Vargaftig

Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis